Mega Lifesciences PCL manufactures, markets and distributes nutritional and herbal supplement, OTC and ethical drugs. The Company produces products that range from treating internal issues to overall general health.

Financial Statement Quarter 3/2025 (Reviewed)

Financial Performance Quarter 3 (F45) (Reviewed)

Management Discussion And Analysis Quarter 3 Ending 30 Sep 2025

Right Of Shareholders To Propose Agenda And Nominees To Be Elected As Company'S Directors, And Submit Questions In Advance For The 2026 Annual General Meeting Of Shareholders

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Mega Lifesciences (MEGA TB)

Financial Statement Quarter 3/2025 (Reviewed)

Financial Performance Quarter 3 (F45) (Reviewed)

Management Discussion And Analysis Quarter 3 Ending 30 Sep 2025

Right Of Shareholders To Propose Agenda And Nominees To Be Elected As Company'S Directors, And Submit Questions In Advance For The 2026 Annual General Meeting Of Shareholders

Financial Statement Quarter 2/2025 (Reviewed)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)